A set of vectors possessing the genes for aspartate semialdehyde dehydrogenase (asd) and the B subunit of the heat-labile enterotoxin of Escherichia coli (LT-B) has been developed. These vectors allow operon or gene fusions of foreign gene epitopes at the C-terminal end of LT-B. Two groups of vectors have been constructed with and without leader sequences to facilitate placing of the foreign antigen in different cell compartments. Two Streptococcus sobrinus genes coding for principal colonization factors, surface protein antigen A (SpaA), and dextranase (Dex), have been fused into the 3' end of the LT-B gene. Resulting protein fusions of -120 to 130 kDa are extremely well recognized by antibodies directed against both SpaA and Dex as well as against LT-B domains and retain the enzymatic activity of dextranase and the biological activity of LT-B in that they bind to GM1 gangliosides. Maximum antigenicity was obtained with the vector possessing an intervening linker of at least six amino acids with two proline residues. Some of the fusion proteins also exhibited another property of LT-B in that they were exported into the periplasm where they oligomerized. LT-B-SpaA and LT-B-Dex hybrid proteins are expressed stably and at a high level in avirulent Salmonella typhimurium vaccine strains which are being used to investigate their immunogenicity and types of induced immune responses. The fusion vectors will also be useful for production and purification of LT-B fusion antigens to be used and evaluated in other vaccine compositions.
Heat-labile enterotoxin (LT-I) produced by human and porcine Escherichia coli isolates and cholera toxin (CT) produced by Vibrio cholerae are closely related. Both proteins manifest significant amino acid homology and share several biochemical and functional properties including the mechanism of action. Periplasmic LT-I consists of five noncovalently bound B subunits and one A subunit. The nontoxic B subunits are responsible for binding the protein to GM, ganglioside located on the surface of intestinal epithelial cells. The A subunit, which undergoes proteolytic cleavage into two fragments (A, and A2), bears enzymatic activity. Intracellularly, the A, protein activates adenylate cyclase, which causes the elevation of the cellular level of cyclic AMP, resulting in watery diarrhea (for a review, see reference 22) .
CT and LT-I are also immunologically related in that they share several common epitopes, as has been demonstrated by neutralization and immunodiffusion assays (9, 10) . Jacob et al. (32) proved that the small synthetic peptides representing the conserved regions of the CT-related enterotoxin family generate an effective cross-reactive immune response. In addition to common antigenic parts, each toxin also has unique determinants in its B subunit (23) .
Recently, a second group of E. coli heat-labile toxins (LT-II) has been described and characterized. Although the LT-II enterotoxin has protein structure and mechanism of action that are characteristic of LT-I, the toxins differ with respect to immunoreactivity and ganglioside-binding specificity (25, 44) . Moreover, no significant nucleotide homology between the genes coding for their B subunits has been observed (43) .
LT-I and CT and their B subunits were described as very strong immunogens which elicit high-titer serum and secretory antibodies when administered into the gut via the oral route in microgram amounts of protein (21, 45) or when delivered to the lymphoid tissue by attenuated Salmonella strains (7, 8, 11) . The B subunits of both enterotoxins also enhance the immunogenicity of relatively poor immunogens when mixed or coupled (chemically or genetically) and given orally (13, 15, 21, 31, 40, 41) . Czerkinsky et al. (13) demonstrated that intragastric immunization of mice with Streptococcus mutans antigen I/II covalently coupled to the B subunit of CT elicits a significant immune response (mucosal and serum immunoglobulin A [IgA] and IgG), although subclinical doses of free CT were required to obtain the optimal antibody response. A vaccine consisting of the B subunit of LT cross-linked to the synthetically produced ST (E. coli heat-stable toxin) (36) has been shown to be immunogenic for both components. A similar immune response was elicited by a vaccine composed of a completely synthetic 44-amino-acid peptide comprising the major antigenic determinant of LT-B joined to ST (31, 35) .
An alternate approach to studying the immune-enhancing effects of the CT-related family of enterotoxins is to construct gene fusions in which genes specifying foreign antigenic determinants are fused to LT-B or CT-B genes. There are several advantages of genetic fusions over chemically synthesized conjugates. First of all, hybrid proteins expressed by genetic fusions should exhibit more defined and homogeneous structure and conformation. It is therefore more likely that the hybrid proteins would retain some native properties of both components. Fused proteins created by genetic manipulations can also be delivered to the gutassociated lymphoid tissue by using attenuated Salmonella strains, a delivery system which has been shown to be an efficient way of stimulating immune responses to recombinant antigens (12) .
Since the mechanisms by which CT or LT or their B subunits enhance desired immune responses are not completely understood (4, 24) , the design of plasmid vectors to generate fusions between parts of these toxins and other antigens will yield compositions that can be used to enhance our understanding of these mechanisms. In this regard, several plasmid vectors which permit gene fusions to the 3' or 5' end of the LT-B or CT-B gene have been constructed (16, 51) . The most extensively studied LT-B or CT-B fusions are the ones with the small, nonimmunogenic E. coli ST (47) (48) (49) . Sanchez et al. (47, 48) constructed a CT-B expression vector in which the structural gene encoding the B subunit of CT was fused to part of the LT-B gene specifying a signal sequence, and the gene fusion was put under control of the strong constitutive tacP promoter. In this system, the authors studied the antigenicity and immunogenicity of CT-B-ST nontoxic hybrid proteins (48) . When tested by injection in rabbits, the chimeric proteins stimulated significant anti-ST and anti-CT-B responses; however, the antisera obtained exhibited low toxin neutralizing activity. They also pointed out the importance of the free carboxyl end of ST for antigenicity of the fused protein. Clements (6) also described the construction of a nontoxic fusion peptide (LT-B-ST) which can be used as a vaccine against an E. coli strain producing both the heat-labile and the heat-stable toxins. Antibodies raised against the purified LT-B-ST chimeric protein were able to recognize both LT-B and ST proteins and also neutralized the biological activity of native ST. Also, an epitope of S. mutans glucosyltransferase fused into the N-terminal end of CT-B (17) and epitopes of the hepatitis B virus joined to the carboxyl end of LT-B (51, 52) resulted in hybrid proteins, which have been shown to be antigenic but not always immunogenic.
In this report, we describe the construction of several Asd+ LT-B+ vectors allowing fusions of foreign genes to the C terminus of LT-B. The Asd+ vectors ensure stable in vivo maintenance in attenuated Aasd Salmonella typhimurium vaccine strains in the absence of external selection (26, 42) . This is because the Aasd mutation confers a requirement for diaminopimelic acid (DAP) (which is not present in animals), such that loss of the vector leads to DAP-less death (26, 42) . To control placing the fused protein antigens in different cell compartments, the LT-B signal sequence was removed from some constructs. Since LT-B has been described as a strong immunogen with immune-enhancing effects and since secretory IgA plays a key role in blocking tooth colonization, we chose two Streptococcus sobrinus genes encoding colonization factors, surface protein antigen A (SpaA) and dextranase (Dex), to be fused to the LT-B gene. Both hybrid proteins (LT-B-SpaA and LT-B-Dex), composed of an approximately 100-kDa streptococcal protein fused to a small 13-kDa LT-B protein, were strongly antigenic and reacted with antibodies directed against both domains (LT-B and streptococcal antigen). Some fused proteins retained other properties of native LT-B, such as the ability to oligomerize (quite possibly into pentamers) and exhibit affinity to GM, and of dextranase to exhibit enzyme activity.
MATERIALS AND METHODS
Strains and growth conditions. Strains and plasmids used in this study are listed in Tables 1 and 2 , respectively. Bacterial strains were grown aerobically at 37°C on L agar or in L broth (39) and when appropriate, ampicillin (50 p,g/ml) (Sigma Chemical Co., St. Louis, Mo.) and DAP (50 p,g/ml) (Sigma) were added.
DNA manipulations. Recombinant clones were screened for plasmid DNA by a modification of the Birnboim (3) alkaline minilysate technique, starting with 1.5 ml of L broth overnight culture. Whenever necessary, plasmid DNA was isolated from 1 liter of L broth overnight culture as described by Sambrook et al. (46) and purified by CsCl-ethidium bromide buoyant density gradient centrifugation. Restriction enzyme digestions and ligation reactions were carried out as described by the manufacturers (International Biotechnologies, Inc., New Haven, Conn.; New England Biolabs, Inc., Beverly, Mass.; Promega Corporation, Madison, Wis.). The recessed 3' termini created by digestion of DNA with restriction enzymes were converted into blunt ends by using the Klenow fragment of DNA polymerase I (IBI). Reactions were carried out for 30 min at 37°C in the presence of 1 mM deoxynucleoside triphosphate. To prevent self-ligation of the vector DNA, 5' phosphate was removed from linearized vector DNA by using calf intestinal alkaline phosphatase from Promega. Oligonucleotides were synthesized by T. Keller, Integrated DNA Chemistry Facility (Biology Department, Washington University). Linkers, if not chemically phosphorylated, were enzymatically phosphorylated by using bacteriophage T4 polynucleotide kinase (New England Biolabs) prior to ligation. Reactions were carried out by the method of Sambrook et al. (46 Tris-acetate-EDTA buffer (46) . Bacteriophage X DNA fragments generated by digestion with HindIII or bacteriophage 4~x174 DNA digested with HaeII were used as molecular size standards (BRL Life Technology Inc., Gaithersburg, Md.). Linear DNA fragments were isolated from agarose gels by using a Prep-A-Gene kit (Bio-Rad) according to the manufacturer's directions.
Electrophoresis of proteins were performed in SDS-10 to 15% polyacrylamide gels by the method of Laemmli (38) . We used Rainbow Markers from Amersham (Arlington Heights, Ill.) as molecular weight standards. Whenever necessary, blue dextran, an indicator substrate for dextranase (Pharmacia LKB Biotechnology AB, Uppsala, Sweden), was incorporated into the SDS-PAGE by mixing the blue dextran to a final concentration of 0.5% prior to the addition of the cross-linking and catalytic agent (2) . After electrophoresis, renaturation of dextranase was performed as previously described (2) .
Western analysis. Protein samples were separated by SDS-PAGE and then electrophoretically transferred to nitrocellulose sheets. The membrane was blocked for 2 h in blocking buffer (100 mM Tris [pH 8.0], 0.25% gelatin, 0.5% bovine serum albumin [BSA], 0.05% sodium azide, 0.04% Tween 80), followed by 2 to 12 h of incubation at room temperature with primary rabbit antibodies (against S. sobnnus SpaA, dilution 1:3,000; against S. sobrinus Dex, dilution 1:3,000; or against E. coli LT-B, dilution 1:1,000; the anti-LT-B serum was the gift of Randall Holmes, Uniformed Services University of the Health Sciences, Bethesda, Md.). These antibodies only recognize the monomeric form of LT-B (ii) Hybridization. LT-B-SpaA clones expressing fusion proteins of low antigenicity were identified by colony hybridization with a probe labeled by using the nonradioactive DNA labeling and detection kit from Boehringer Mannheim Bio-Chemical Co, Indianapolis, Ind. The Bluescript-pKSII (Strategene, La Jolla, Calif.) plasmid with the spaA gene cloned into it, pYA3085, was labeled with digoxigenin dUTP by a random primed reaction. Hybridizations and immunological detection of the positive clones were performed as recommended by the manufacturer.
(iii) Blue dextran assay. Clones producing enzymatically active dextranase were identified by the blue dextran assay (33 
RESULTS

Construction and properties of the family of LT-B+ vectors.
A set of Asd+ LT-B+ vectors allowing fusion of foreign epitopes to the C-terminal end of LT-B has been constructed. The vectors can be divided into two groups: those with and those without a signal sequence, which is necessary for LT-B to be transported into the periplasm. pYA810, which is pYA292 (26) lacking a 0.16-kb HindIII-HindIII lacZa DNA fragment, has been used as the starting plasmid for all constructions. pYA292 is a component of the balanced lethal host-vector system developed in our laboratory (42) .
In this system, the asd+ gene from S. typhimunium, a non-drug resistance selectable marker, is present on the plasmid vector DNA and complements an asd gene deletion present in the host bacterial chromosome (26, 42) .
The plasmid EWD299 (14), which is a derivative of pBR313, codes for porcine LT and was our source of the LT-B gene. We cloned a 584-bp Sau3A-MaeI DNA fragment of pEWD299 into pYA810 digested with BamHI and PstI by using MaeI-PstI oligonucleotide linkers of different length and nucleotide composition. This strategy removed the translational stop codon but left the codon for the terminal LT-B asparagine residue intact. Figure 1A presents the way in which the LT-B vectors were constructed as well as restriction maps of the Asd+ LT-B+ vectors. The linkers contained amino acid codons which are translated with high efficiency by E. coli cells. To minimize the conformational changes of LT-B, codons specifying rather small, uncharged amino acids were included, whenever possible. Even so, when codons for five amino acids (Tyr, Ala, Cys, Thr, and Ser) were added to the 3' end of the LT-B gene, one of the constructs specified a protein which was not exported into the periplasm and was cytotoxic for the E. coli host cell whenever expression of the LT-B gene was induced (data not shown). Therefore, it seems that specification of amino acids that are hydrophobic results in an unacceptable linker, a result originally noted by Sandkvist et al. (50) . Four other vectors were therefore constructed by using 42-bp linkers specifying less hydrophobic amino acids (37) to yield pYA2906, pYA3047, pYA3048, and pYA3049 (Fig. 1) .
To be able to place the fusion proteins in different cell compartments, nucleotides specifying a 23-amino-acid leader sequence have been deleted from the LT-B gene. We took advantage of the Sacl recognition site which is located at the beginning of the coding sequence for the mature LT-B protein. pYA3047 and pYA3048 plasmid DNAs were digested with EcoRI and SacI and religated by using an 8-bp single-stranded oligonucleotide (5' AATTAGCT 3') to yield pYA3081 and pYA3082 (Fig. 1A) . These constructs lack a 287-bp DNA fragment and also lost EcoRI and SacI restriction sites. Figure 1B presents the nucleotide and deduced amino acid sequences of the multiple cloning sites located at the 3' end of the LT-B gene. All vectors with unique restriction sites located in the multiple cloning site (MCS) permit cloning of foreign DNA in three different reading frames and also provide termination stop codons. Moreover, the MCS nucleotide sequences of pYA3047, pYA3048, and pYA3049 code for proline and glycine residues to create kinks that interrupt the a-helix and thus permit a more natural conformational structure between the domains of the LT-B and the fused protein. All vectors encode the full-length LT-B fragment plus nine amino acids added to the carboxyl end of the protein. The B subunits of LT are synthesized as precursors, which are then processed and translocated through the cytoplasmic membrane. When present in the periplasmic space, they form an oligomer (presumably a pentamer) which dissociates into constituent monomers only after heating to >70'C (28, 30) . It was of interest to determine if the C-terminal extensions influenced the ability of LT-B to oligomerize. Crude protein extracts from E. coli X6097 carrying Asd+ LT-B' vectors lysed by 0.5% SDS at 100 or 60°C have been analyzed by SDS-PAGE and Western blot analysis (Fig. 2) . The protein monomers of -13 kDa specified by all of the Asd+ LT-B' vectors with leader sequences react with anti-LT-B antibodies (Fig. 2, lanes 1A, 2A, 3A of LT-B with different C-terminal extensions, as well as native LT-B encoded by pEWD299, do not react with the anti-LT-B antibodies used in these studies (Fig. 2, lanes 1B , 2B, 3B, and 4B). Vectors lacking signal sequences expressed proteins of monomeric size of approximately 13 kDa (Fig. 2 , lanes 7A and 8A) which do not oligomerize (Fig. 2, lanes 7B  and 8B) . These cytoplasmic proteins differ from the mature form of LT-B encoded by pYA3047 and pYA3048 by having four amino acids (Met, Pro, Glu, and Leu) added to the N terminus. These alterations at both the C-and N-terminal ends of LT-B do not abolish antigenicity.
All Asd+ LT-B+ vectors were introduced by electroporation into the attenuated oral S. typhimurium Acrp Acya Aasd vaccine strains X4072 and X3987 in which the LT-B gene was expressed at a high level (data not shown).
Gene fusions at the carboxyl end of LT-B. Two S. sobrinus genes coding for important colonization antigens, surface protein antigen A (SpaA) and dextranase (Dex), have been fused to the 3' end of the LT-B gene. The main antigenic determinants of the spaA gene have been previously characterized (27) and recloned into the Asd+ vector pYA292 to yield pYA2905 (18) . The following strategy has been employed to construct the LT-B-spaA gene fusion. pYA2905 plasmid DNA was digested completely with SmaI and then partially with EcoRI. A 2.7-kb EcoRI-SmaI fragment of pYA2905 isolated from an agarose gel was ligated between the EcoRI and SmaI restriction sites of the pBluescript II KS plasmid (Stratagene), yielding pYA3085, which was the source of the spaA gene for the next constructs. The spaA gene cloned into pKSII is out of frame. However, when pYA3085 DNA was cut with EcoRV and SmaI, the fragment containing the spaA gene could be ligated into ApaLIdigested, Klenow-treated DNA of the Asd+ LT-B' vector DNA (Fig. 1) , in the proper reading frame. Initially, ApaLIcut, Klenow-treated pYA2906 DNA was ligated with the 2.7-kb EcoRV-SmaI fragment of pYA3085. The ligation mixture was used to transform E. coli X6097 carrying pYA812 (a pBR322 derivative with the lacIq gene). Transformants were selected for the Asd+ phenotype and screened for the presence of the spaA gene product after induction with 1 mM isopropylthio-3-D-galactopyranoside (IPTG) by colony immunoblot. No strong immunologically reactive clone was found. Next, pYA3085 DNA was labeled by randomly primed nonradioactive digoxigenin-dUTP and used as a probe for colony hybridization. With this screening method, several clones containing spaA DNA fused into the LT-B gene were identified. Plasmid DNA was isolated from one of them, designated pYA3086, and the construct was verified by restriction analysis. Properties of the fused protein specified by this construct are described below.
The same 2.7-kb EcoRV-SmaI fragment of pYA3085 was ligated into ApaLI-cut, Klenow-treated DNA of Asd+ LT-B+ vectors whose MCSs code for proline residues. In every case, we obtained several immunologically reactive clones. We isolated pYA3055, which was derived from pYA3047; pYA3056, which was derived from pYA3048; and pYA3057, which was derived from pYA3049. All of them specified LT-B-SpaA-fused proteins, which behaved identically in every checked respect. Figure 3 presents the restriction map and the relevent nucleotide and amino acid sequence for pYA3056, which was chosen for further analysis.
We also fused the same 2.7-kb DNA fragment coding for the SpaA protein into the 3' end of the LT-B gene from which the signal sequence had been removed (pYA3082). In this experiment, only one immunologically positive clone carrying stable recombinant plasmid DNA of molecular weight of -6.5 kb was isolated. Single and double restriction enzyme analysis of the plasmid DNA from this clone, designated pYA3091, revealed that part of the spaA gene had been deleted. The deletion, which is approximately 100 bp long, covers the EcoRI site and the first SstI site located near the junction point between the two genes (Fig. 3) .
pYA993 (56) is a pBR322 derivative into which a major part of the S. sobrinus dextranase gene has been inserted. The S. sobrinus dextranase gene has been cloned (1) and sequenced in our laboratory (57) . Studies are in progress to understand how dextranase activity is regulated and its involvement in the caries-forming process (54) . A 2.6-kb PvuII DNA fragment of pYA993 was purified from an agarose gel and inserted in frame into SalI-digested and blunt-ended (Klenow) pYA3049 or BamHI-digested and blunt-ended (Klenow) pYA3047 and pYA3048. The ligation mixtures were used to transform E. coli X6098 carrying pYA812. Transformants were selected for the Asd+ phenotype and screened for expression of the enzymatically active dextranase by the blue dextran plate assay. We isolated pYA3058 derived from pYA3048, pYA3073 derived from pYA3047, and pYA3088 derived from pYA3049. However, it should be mentioned that this last plasmid, pYA3088, expressed dextranase with weak enzymatic activity. Figure 4 presents construction of the LT-B-Dex fusions, as well as the nucleotide and deduced amino acid sequences at the junction point between the two domains of the chimeric proteins.
Employing the same strategy, we also fused the dextranase gene of pYA993 into the 3' end of the LT-B gene of pYA3082 (LT-B without leader sequence). This construct was designated pYA3083. Construction of all LT-B-Dex fusions was verified by restriction enzyme analysis.
Characterization of the LT-B fusion proteins. First, we investigated properties of the chimeric proteins expressed by the Asd+ LT-B+ vectors containing the LT-B leader sequence, which is necessary for the proteins to be transported into the periplasm and oligomerize, presumably into a pentamer. The LT-B-SpaA protein expressed by pYA3086, which has an 8-amino-acid linker with no proline residues inserted between the last amino acid of LT antibodies, as determined by Western blot analysis (data not shown). Three other LT-B-SpaA fusions specified chimeric proteins which contained a 10-amino-acid linker with two proline residues inserted between the terminal asparagine of LT-B and the first glycine of SpaA. Figure 5 shows the Western blot analysis of the crude protein extract from E. coli X6097 containing pYA3056. Although we have fused the large SpaA (-120-kDa) protein with the small 13-kDa LT-B, the resulting hybrid protein still exhibits strong antigenicity and reacts with antibodies directed against both moieties. The chimeric protein specified by pYA3056 (Fig. SB, lanes 4 and 5) migrates slightly slower than the SpaA protein encoded by pYA2905 (Fig. SB, lane 6) . LT-B-SpaA protein, as well as the spaA gene product alone (27) , is proteolytically degraded in E. coli cells. Degradation products can be detected by anti-SpaA antibodies but are not recognized by anti-LT-B antibodies, which implies that degradation is more from the N-terminal than the C-terminal end.
Cold osmotic shock followed by Western blot analysis of the proteins located in different cell compartments revealed evidence of the periplasmic location of the LT-B-SpaA fusion protein specified by pYA3056 (data not shown). However, there was no evidence of oligomer formation (Fig.  5, lane 5) . One can conclude that the LT-B-SpaA oligomer either does not form or is extremely unstable. Even when we lysed cells at 37°C in 0.5% SDS, LT-B-SpaA fusion proteins were present as monomers. Blocking of the carboxyl end of the LT-B might be responsible for this effect.
The LT-B-SpaA hybrid protein gene is transcribed from a repressible trc promoter. The E. coli strain containing pYA3056 also possesses a pBR322 derivative that has the laclq gene coding for lac repressor (pYA812). pYA812 has a higher copy number per cell than the Asd+ vectors (26, 42) . However, expression of the chimeric proteins is not completely shut off, even in the absence of IPTG (Fig. 5, lane 3) . The addition of IPTG results in a slower growth rate and eventual lysis of the cells. weak enzymatic activity, and both its components lost antigenicity. Contrary to that, antigenic determinants encoded by dextranase and LT-B genes are recognized by their respective antibodies in the two other fusion proteins specified by pYA3058 (Fig. 6 ) and pYA3073 (data not shown), which also display strong dextranase enzymatic activity. Both of them contain a linker of 6 amino acids with two proline residues. The LT-B-Dex fusion protein specified by pYA3058 is transcribed from the trc repressible promoter because in the presence of Laclq specified by pYA812, its expression is dependent upon the addition of IPTG. The addition of IPTG also results in slowing the growth rate of X6098 (pYA812 and pYA3058). SDS-PAGE also showed that the fusion protein encoded by pYA3058 (Fig. 6B, lane 2) was slightly bigger than the one specified by pYA3010 (Fig. 6B , lanes 5 and 6) and exhibits properties characteristic of LT-B itself in that it forms a high-molecular-weight (> > >200,000) complex (Fig. 6, lane 1) . We did not fully characterize these oligomeric forms, but their high molecular weight, their inability to react with antibodies that only recognize monomeric LT-B, and their ability to bind to GM1 ganglioside (see below) lead us to believe that these oligomers are probably pentamers. The oligomeric form of the LT-B-Dex fusion reacted with both anti-LT-B (Fig. 6A, lane 1) dextranase (Fig. 6B, lane 1) antibodies, in contrast to the oligomeric form of LT-B specified by the vector alone, which did not react with the anti-LT-B serum (Fig. 2, lane  2B) . In recent experiments, we have used an anti-LT-B serum raised against purified LT-B pentamer, and these antibodies reacted with nonfused and fused LT-B monomers and oligomers. Heating of the LT-B-Dex fusion protein at 60°C resulted in the presence of both the oligomeric and monomeric forms of the hybrid. Most likely, the oligomeric form of the fused protein is less heat stable than the pentameric form of LT-B alone. When cells were lysed at 37°C, more than 80% of the LT-B-Dex hybrid protein encoded by pYA3058 existed as an oligomer (data not shown). However, extensive degradation of the protein made analysis difficult. Since the LT-B-Dex fusion protein oligomerized, it was of interest to determine its cellular location. Periplasmic and cytoplasmic protein extracts of E.
coli X6098 (pYA3058) were prepared by cold osmotic shock and analyzed by SDS-blue dextran-PAGE. Dextranases encoded by pYA993 and by pYA3010 were used as controls. The dextranase gene of pYA993, transcribed from the tet promoter, is expressed as a fusion with the tet gene, and the protein is exported into the periplasm (Fig. 7, lane 2) . Expression of the dextranase gene of pYA3010 is driven by the trc promoter of pYA292 and specified cytoplasmic dextranase (Fig. 7, lane 1) . By comparing the intensity of the enzymatic reactions (hydrolysis of the blue dextran) exhibited by the periplasmic and cytoplasmic protein fractions, we concluded that the LT-B-Dex fusion specified by pYA3058 (Fig. 7, lane 3) is translocated into the periplasm. Cold osmotic shock caused release of some cytoplasmic protein, since in the case of pYA3010 dextranase is present in both fractions (Fig. 7, lane 2) . Figure 8 presents data on the antigenic properties of the LT-B fusions which lack leader sequences. Both LT-B-SpaA (specified by pYA3091) and LT-B-Dex (specified by pYA3083) are expressed at high level in S. typhimurium X3987 and retain antigenicity of both components. The cellular location of these hybrid proteins has been checked by cold osmotic shock followed by SDS-blue dextran-PAGE for the LT-B-Dex fusion (Fig. 7, lane 4) and Western blot analysis for the LT-B-SpaA chimera (data not shown). Both are cytoplasmic.
It was of interest to determine if the LT-B-streptococcal antigen fusions still retained the biological activity of LT-B.
GM1 ganglioside was bound to the surfaces of plastic microtiter plates and reacted with crude protein extracts obtained from E. coli X6097 or S. typhimunium X3987 cells containing different LT-B fusions. LT-B expressed by pYA3048 (LT-B with leader sequence) with a 10-amino-acid extension on its carboxyl end exhibited affinity to GM1 ganglioside identical to that of LT-B specified by the original pEWD299 plasmid, while cytoplasmic LT-B specified by pYA3082, which does not oligomerize, also lost the ability to efficiently bind to GM1 gangliosides. Interestingly, both fusions containing leader sequences display the same level of affinity to GM1 even though they differ from each other in their abilities to oligomerize and in the stabilities of the oligomer forms. LT-B-streptococcal antigen fusions which do not contain signal sequences and stay cytoplasmic, do, however, retain low levels of GM1 ganglioside affinity. vectors which allow transcriptional and translational fusions of foreign gene epitopes in every reading frame into LT-B with or without leader sequences. We chose two immunogenic S. sobrinus antigens, SpaA (18) and dextranase (57) , to be fused to the C-terminal end of LT-B. They are encoded by a 2.7-kb EcoRI-SmaI DNA fragment of pYA2905 specifying SpaA and a 2.6-kb PuvII DNA fragment of pYA993 specifying Dex, respectively.
In order to stimulate an immune response to an antigen fused to LT-B, the hybrid protein should retain the native properties of the two components, including the ability to bind antibodies. Genetic fusions of >100-kDa streptococcal antigens into the 13-kDa LT-B resulted in chimeric proteins which are recognized by anti-serum against both LT-B and the streptococcal antigens. Linkers of different nucleotide sequences introduced into the carboxyl end of the LT-B gene permitted us to study the influence of the length and amino acid composition of the intervening linker on the antigenicity of the hybrid protein. It has been noted before (48) that even minor modification of the amino acid composition of the CT-B-ST fusion affects its reaction with antibodies. Clements (6) showed that a lack of the linker between the two domains of the LT-B-ST fusion completely abolished antigenicity, which could be restored by introducing a 7-amino-acid proline-containing linker. In this study, maximum antigenicity for both components of LT-B fusions has been obtained for linkers of at least 6 amino acids with two proline residues. Antigenic determinants encoded by the LT-B component of the fusion protein specified by pYA3086 (with an 8-amino-acid-long linker containing no proline residues) are not presented in the proper way to be able to combine with antibodies against LT-B; moreover, conformational changes of the protein also diminished the immunoreactivity of the SpaA epitopes. Three other LT-B-SpaA fusions specified by pYA3055, pYA3056, and pYA3057 (with 10-amino-acid-long linkers containing two proline residues) retained strong antigenicity to both anti-LT-B and anti-SpaA antibodies. On the basis of the properties of the constructed LT-B-SpaA protein fusions, one can conclude that substitution of a slightly hydrophilic glycine by highly hydrophobic valine (compare MCS of pYA3047 and pYA3048 [ Fig. 1]) or inclusion of a charged amino acid (asparagine encoded by the MCS of pYA3047 and pYA3048 but not by pYA3049) does not appreciably influence the conformation of the fused protein.
Analogous findings were made for the LT-B-Dex fusions. The LT-B-Dex fusion protein specified by pYA3088 (5-amino-acid-long linker with one proline residue) not only lost the ability to react with antibodies directed against either domain, but its biological activity had also been diminished. But when S. sobrinus dextranase was fused into the carboxyl end of LT-B with the help of 6-amino-acid-long linkers containing two prolines (pYA3058 and pYA3073), the resulting chimeras were well recognized by anti-LT-B and antiDex antibodies. Moreover, the hybrid proteins exhibited strong enzymatic activity.
The immunity-enhancing ability of CT-B and LT-B in stimulating mucosal immune responses could be due to the presence of T-and B-cell epitopes, the conformation and size of oligomeric forms, the ability to interact with GM1 gangliosides to facilitate endocytosis, and the potential to block induction of tolerance. Most likely, for an LT-B fusion to be effective as an oral vaccine, it is important to retain abilities to pentamerize and bind to GM1 gangliosides. All previously reported N-terminal fusions (16, 48) can pentamerize, but fusions blocking the carboxyl terminus of the toxin often resulted in diminishing pentamerization. On the basis of crystallographic studies of the LT toxin, Sixma et al. (53) concluded that LT-B elongated at the COOH end cannot form the AB5 structure. Using the appropriate linker, we constructed two LT-B-Dex fusions of monomeric molecular mass of approximately 120 kDa, which were translocated into the periplasm where they oligomerized. Furthermore, ganglioside-binding properties of the toxin have been shown to be more affected by C-than by N-terminal fusions (5, 6, 17) . GM1 binding experiments showed that all constructed LT-B fusions retained biological activity of LT-B in that they bound to GM1 gangliosides, but incorporation of the foreign antigen into the carboxyl terminus of LT-B influences their affinity. Interestingly, two fusions (pYA3091 and pYA3083 [ Fig. 9 ]) without leader sequences still retained a low-level GM1 ganglioside affinity. It should be pointed out that the LT-B protein encoded by pYA3082 (LT-B without leader sequence) did not, however, react by the same assay with GM1. One can conclude that incorporation of an approximately 100-kDa protein into the carboxyl end of LT-B can allow the GM1 binding domain to be presented in the proper way. Experiments to purify large amounts of the LT-B fusion proteins, which will allow us to investigate GM1 binding properties in more defined ways, are now in progress.
It was a common belief (17) that to minimize any structural changes of the LT-B, the size of the protein fused into it should be kept to a minimum. In this study, we proved that a properly designed linker providing separation of domains permitted retention of antigenicity and biological activities of both components of the hybrid protein, even when the foreign antigen is 10 times larger than LT-B alone.
Since S. typhimurium establishes an infection by first later. These effects were much more evident at 37 than at 30°C. The same effect has also been noticed by others (17) . On the other hand, N-terminal as well as C-terminal CT-B-ST fusions described by Sanchez et al. (48) , when introduced into V. cholerae strains, were secreted into the medium and were not toxic, even though they were expressed from the strong constitutive tacP promoter. Our preliminary results indicate that recloning of LT-B gene fusions into an Asd+ vector with the pSC101 plasmid replicon in place of the piSA replicon lowers the amount of the expressed protein to a level which is not cytotoxic. We hope that under these circumstances the amount of the expressed antigen will be high enough to stimulate an immune response. If not, we can use the Asd+ balanced lethal hostvector system construct described in this report to select more rapidly growing variants which should be due to mutations that reduce the toxicity of fused antigen synthesis. This selection can be done either in vitro or in vivo. Recovered isolates would have to be screened for high-level expression of a fusion protein with the antigenic, biological, and/or enzymatic activities displayed by the parental strain with the original construct. DNA sequencing would then be carried out to identify the specific mutational alterations that eliminated toxicity associated with high-level expression. This might then permit even higher levels of antigen synthesis by changing the piSA plasmid replicon to a higher-copynumber replicon. Two of our constructs, pYA3083 and pYA3091, specifying cytoplasmic LT-B-Dex and LT-B-SpaA, respectively, have been introduced into the avirulent oral S. typhimurium Acrp Aasd Acya vaccine strain X3987 (19, 20) . We are now using these constructs to evaluate the immunogenicity of the LT-B fusions as well as to compare the types of immune responses induced by S. sobnnus antigens alone with those induced by the same antigen as an LT-B fusion protein. Moreover, we have also constructed LT-B-Dex (34) and LT-B-SpaA operon fusions (unpublished data). Studies are in progress to determine the immunological properties of the S. sobrinus antigens as operon or gene fusions with LT-B. This will allow us to better understand the mechanisms by which LT-B exerts its immunity-enhancing effect.
